An Alto drug candidate for major depressive disorder failed to meet primary and secondary goals of a placebo-controlled Phase 2b test. The disappointing result could stymie plans for further tests of the small molecule in PTSD and bipolar depression.
The post Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral appeared first on MedCity News.
